ERBB4 and glioblastoma: The ‘uniqueness’ of ErbB4 in the ErbB receptor family, epitomized by its isoform variations, tissue- and disease state-specific expression, vast array of activating ligands (and yet, a seemingly selective subset of downstream targets), and large number of tyrosine phosphorylation sites makes it an attractive potential target to treat diseases such as GBM.